BDPT

BIOADAPTIVES, INC.

OTC · HEALTH CARE · PHARMACEUTICAL PREPARATIONS

0.00

−0.00 −6.25%

USD · close Oct 22

A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up

Work order

FLAG · shorts 0

Insiders, 90 days

no open-market filings in 90 days

Congress, 90 days

0 / 0

no disclosures naming it

Big money

0 / 15

none of the tracked funds disclose it

Calls on record

nobody we score has called it yet

MKT CAP $295KP/E —DIV YIELD —FCF YIELD —REV TTM $26K +694.1%NET INCOME −$1.2MNET CASH —52W 0.00 – 0.05SEC XBRL · TTM TO Invalid Date

How BDPT rewrote its risk factors

10-K ITEM 1A · FY2024 → FY2025

Text kept

41%

of sentences unchanged

Added

new sentences

Dropped

sentences removed

Length

+82

words, now 3,907

New in FY2025

The Company faces considerable risks in its business plan and a potential shortfall of funding due to uncertainty in our ability to raise adequate capital in the equity securities market.
During the period ended December 31, 2024, there is no sales revenues to cover our expenses so that we were reliant on investment funding to continue operations.
However, these products are still in development stage and will not be on market till first or second quarter of 2025.
The Company believes that its expectations as to its ability to secure additional capital are reasonable, but there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.
The Company acknowledges that its Plan of Operations may not result in the consistent generation of positive working capital in the near future.
Although management believes that it will be able to successfully execute its business plan, which includes third party financing and the raising of capital to meet the Company’s future liquidity needs, there can be no assurances.
These matters raise substantial doubt about the Company’s ability to continue as a going concern We currently rely on certain key individuals, and the loss of one of these key individuals could have an adverse effect on the Company.
The Company’s success will be dependent in part upon its ability to attract qualified personnel and consultants.
The Company’s success will be dependent in part upon its ability to attract qualified creative marketing, sales and development professionals.
The Company’s business plan anticipates that operations will undergo significant expansion during 2024 and beyond.
This expansion will require the Company to manage a larger and more complex organization, which could place a significant strain on our managerial, operational and financial resources.
Failure to expand in an efficient manner could cause expenses to be greater than anticipated, revenues to grow more slowly than expected and could otherwise have an adverse effect on the business, financial condition and results of operations.
In addition, it is possible that additional or revised Federal, State and Local laws and regulations may be enacted in the future governing the mining industry.
There can be no assurance that the Company will be able to comply with any such laws and regulations and its failure to do so could significantly harm our business, financial condition and results of operations.
Our planned operations will be subject to risks normally incidental to our business activities and will be dependent on internal and third-party production and distribution operations that could result in work stoppages, damage to property or unavailable product for resale.
Unanticipated allergic or other reactions.
We market products that are ingested by our customers and run additional risks incumbent to sales of this manner of consumer good.
Our existing insurance coverage would almost certainly be inadequate to deal with any manner of mass tort claim and the ability of our suppliers to indemnify us is uncertain.
Additionally, our contract suppliers are reliant on source materials that are imported from China and other countries, so that we are subject to risks associated with interruptions or pricing increases due to political and other reasons.
While we believe our whole plant- and algal-mushroom based products have unique benefits that should lead to commercial success, BioAdaptive’s ability to effectively compete could be hindered by a lack of funds, poor positioning, management error, and other factors.
RISKS RELATED TO OUR PUBLIC COMPANY STATUS AND OUR COMMON STOCK Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public.
As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees.
During the course of our testing, we may identify other deficiencies that we may not be able to timely remediate.
In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes Oxley”).
Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.
As a public company, we are required to comply with numerous financial reporting and legal requirements, including those pertaining to audits and internal control.
If our revenues do not increase and/or we cannot satisfy many of these costs through the issuance of our shares, we may be unable to satisfy these costs in the normal course of business that would result in our being unable to continue as a going concern.
The Articles of Incorporation and Bylaws of BioAdaptives provide for indemnification of directors and officers at the expense of the respective corporation and limit their liability.
This may result in a major cost to the corporation and hurt the interests of stockholders because corporate resources may be expended for the benefit of directors and officers.
The market for the BioAdaptives Shares is extremely limited and sporadic.
These factors may impact on our ability to obtain financing in the future and will certainly have an impact on the value of our common stock for shareholders.
BioAdaptives’ common stock is a penny stock, which is restricted by the SEC’s penny stock regulations and FINRA’s sales practice requirements, which may limit a stockholder’s ability to buy and sell our common stock.
The SEC has adopted Rule 15g-9 which generally defines “penny stock” to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions.
Our common stock is covered by these rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and accredited investors.
Prior to recommending speculative low -priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information.
Under interpretations of these rules, the FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers.
FINRA’s requirements make it more difficult for broker-dealers to recommend that their customers buy BioAdaptives’ common stock, which may limit investor ability to buy and sell our common stock.
Such patterns include: control of the market for the security by one or a few broker-dealers that are often related to a promoter or issuer. manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases. boiler room practices involving high pressure sales tactics and unrealistic price projections by salespersons. excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.
Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock.

and 16 more.

Gone since FY2024

Due to uncertainty in our ability to raise adequate capital in the equity securities market, the company faces considerable risks in its business plan and a potential shortfall in funding.
During the period ended December 31, 2024, there is no sales revenue to cover our expenses so that we were reliant on investment funding to continue operations.
However, these products are still in the development stage and will not be on market till first or second quarter of 2025.
The Company believes that its expectations as to its ability to secure additional capital are reasonable.
Still, there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.
The Company acknowledges that its Plan of Operations may not produce a consistent generation of positive working capital shortly.
Although management believes it will be able to successfully execute its business plan, which includes third-party financing and raising capital to meet the Company’s future liquidity needs, there can be no assurances.
These matters raise substantial doubt about the Company’s ability to continue as a going concern.
We currently rely on certain key individuals, and the loss of one of them could adversely affect the Company.
The Company’s success will depend in part on its ability to attract qualified personnel and consultants.
The Company’s success will depend in part upon its ability to attract qualified creative marketing, sales, and development professionals.
The Company’s business plan anticipates that operations will significantly expand during 2025 and beyond.
This expansion will require the Company to manage a larger and more complex organization, which could significantly strain our managerial, operational, and financial resources.
Failure to expand efficiently could cause expenses to be greater than anticipated, revenues to grow more slowly than expected, and could otherwise have an adverse effect on the business, financial condition, and results of operations.
In addition, additional or revised Federal, State, and Local laws and regulations may be enacted in the future governing the mining industry.
There can be no assurance that the Company will be able to comply with any such laws and regulations.
Failure to do so could significantly harm our business, financial condition, and results of operations.
Our planned operations will be subject to risks ordinarily incidental to our business activities.
They will depend on internal and third-party production and distribution operations that could result in work stoppages, property damage, or unavailable products for resale.
Unanticipated allergy or other reactions.
We market products that our customers ingest and run additional risks incumbent on the sales of these consumer goods.
Our existing insurance coverage would almost certainly be inadequate to deal with any mass tort claim, and the ability of our suppliers to indemnify us is uncertain.
Additionally, our contract suppliers rely on source materials imported from China and other countries.
Hence, we are subject to risks associated with interruptions or pricing increases due to political and other reasons.
While we believe our whole plant, fungi, and algal-based products have unique benefits that should lead to commercial success, BioAdaptive’s ability to effectively compete could be hindered by a lack of funds, poor positioning, management error, and other factors.
RISKS RELATED TO OUR PUBLIC COMPANY STATUS AND OUR COMMON STOCK Our internal controls may be inadequate, which could make our financial reporting unreliable and lead to the dissemination of misinformation to the public.
As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.
We do not have a sufficient number of employees to segregate responsibilities.
We may be unable to increase our staff or engage outside consultants or professionals to overcome our lack of employees.
During our testing, we may identify other deficiencies that we may not be able to remediate promptly.
In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have adequate internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes Oxley”).
Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are essential to help prevent financial fraud.
As a public company, we must comply with numerous financial reporting and legal requirements, including those pertaining to audits and internal control.
If our revenues do not increase and/or we cannot satisfy many of these costs through the issuance of our shares, we may be unable to satisfy these costs in the normal course of business, resulting in our inability to continue as a going concern.
The Articles of Incorporation and Bylaws of BioAdaptives provide for the indemnification of directors and officers at the expense of the respective corporation and limit their liability.
This may result in a significant cost to the corporation and hurt the interests of stockholders because corporate resources may be expended for the benefit of directors and officers.
The market for the BioAdaptives Shares is minimal and sporadic.
These factors may impact our ability to obtain financing in the future and will undoubtedly impact the value of our common stock for shareholders.
BioAdaptives’ common stock is a penny stock, which is restricted by the SEC’s penny stock regulations and FINRA’s sales practice requirements.
These restrictions may limit a stockholder’s ability to buy and sell our common stock.

and 26 more.

Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.

Watch BDPT. Know when insiders buy.

One email the day a filing lands. Free.